The Benefits of Olanzapine in Palliating Symptoms

被引:17
作者
Davis, Mellar P. [1 ]
Sanger, Gareth J. [2 ,3 ]
机构
[1] Geisinger Med Ctr, 100 N Acad Ave, Danville, PA 17822 USA
[2] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[3] Queen Mary Univ London, Natl Bowel Res Ctr, Barts & London Sch Med & Dent, London, England
基金
英国医学研究理事会;
关键词
Olanzapine; Nausea; Vomiting; Appetite; Advanced cancer; Substance abuse; CHEMOTHERAPY-INDUCED NAUSEA; ATYPICAL ANTIPSYCHOTIC-DRUGS; DOUBLE-BLIND; ADVANCED CANCER; IN-VITRO; 2ND-GENERATION ANTIPSYCHOTICS; MUSCARINIC RECEPTORS; ANTIEMETIC THERAPY; CIGARETTE-SMOKING; AREA POSTREMA;
D O I
10.1007/s11864-020-00804-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Opinion Statement Olanzapine has become a major drug in the management of chemotherapy-induced nausea and vomiting as a prophylactic agent. In addition, a recent randomized trial has demonstrated its benefits in treating nausea and vomiting associated with advanced cancer. The added benefit to olanzapine is that it also stimulates appetite. As a result, since it treats multiple symptoms associated with advanced cancer, it is likely to become the antiemetic of choice in palliative care at least in the USA. The added benefit of treating insomnia and the avoidance of benzodiazepines should place olanzapine in at the top of the list of drugs to use for patients who do complain of insomnia. There is no good evidence that it potentiates the respiratory depression of opioids unlike benzodiazepines. The evidence is weak that olanzapine in as an adjuvant analgesic. Hopefully, future trials will explore this in greater depth. The benefits of adding olanzapine to potent opioids are that it may reduce craving, drug cues, and opioid misuse. Other symptoms like anxiety and depression may be addressed by the addition of olanzapine to standard antidepressants.
引用
收藏
页数:20
相关论文
共 176 条
[1]   Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder [J].
Abrams, Paul ;
Andersson, Karl-Erik ;
Buccafusco, Jerry J. ;
Chapple, Christopher ;
de Groat, William Chet ;
Fryer, Alison D. ;
Kay, Gary ;
Laties, Alan ;
Nathanson, Neil M. ;
Pasricha, Pankaj Jay ;
Wein, Alan J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (05) :565-578
[2]   Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia [J].
Akerele, Evaristo ;
Levin, Frances R. .
AMERICAN JOURNAL ON ADDICTIONS, 2007, 16 (04) :260-268
[3]   Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis [J].
Alhifany, Abdullah A. ;
McBride, Ali ;
Almutairi, Abdulaali R. ;
Cheema, Ejaz ;
Shahbar, Alaa ;
Alatawi, Yasser ;
Alharbi, Adnan S. ;
Babiker, Hani ;
MacDonald, Karen ;
Aapro, Matti ;
Abraham, Ivo .
SUPPORTIVE CARE IN CANCER, 2020, 28 (03) :1031-1039
[4]   Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction [J].
Andrews, PLR ;
Sanger, GJ .
CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (06) :650-656
[5]   Effects of atypical antipsychotic drugs on QT interval in patients with mental disorders [J].
Aronow, Wilbert S. ;
Shamliyan, Tatyana A. .
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
[6]  
Bagdy G, 1996, BEHAV BRAIN RES, V73, P277
[7]   Prior Haloperidol, but not Olanzapine, Exposure Augments the Pursuit of Reward Cues: Implications for Substance Abuse in Schizophrenia [J].
Bedard, Anne-Marie ;
Maheux, Jerome ;
Levesque, Daniel ;
Samaha, Anne-Noel .
SCHIZOPHRENIA BULLETIN, 2013, 39 (03) :692-702
[8]  
Berk M, 1999, INT CLIN PSYCHOPHARM, V14, P177, DOI 10.1097/00004850-199905002-00005
[9]   Combined Use of Duloxetine and Olanzapine in the Treatment of Urologic Chronic Pelvic Pain Syndromes Refractory to Conventional Treatment: A Case Report [J].
Bi, Bo ;
Shan, Liping ;
Zhou, Die .
CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2018, 16 (01) :122-125
[10]  
Browning KN, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00413